Aegerion CEO Talks Juxtapid Launch, Competitive Threats At BIO
This article was originally published in The Pink Sheet Daily
Executive Summary
Aegerion CEO Marc Beer outlined why he thinks Juxtapid will emerge as the first-line treatment of choice for the orphan lipid disease HoFH over Genzyme/Isis’ Kynamro despite its significantly higher cost during an interview at the BIO CEO & Investor conference; the two drugs are facing off to win patients in an ultra-niche market that could total just 3,000 patients in the U.S.
You may also be interested in...
Voice of the Patient: Peer “Ambassadors” Help Recruitment at Aegerion
In the ultra-orphan, ultra-priced segment where the recruitment of each patient is a major commercial event, the voice of existing patients can be very important.
Voice of the Patient: Peer “Ambassadors” Help Recruitment at Aegerion
In the ultra-orphan, ultra-priced segment where the recruitment of each patient is a major commercial event, the voice of existing patients can be very important.
Genzyme/Isis Build Simple, No Fuss Case For Weekly Cholesterol Injectable Kynamro
Genzyme and Isis are playing up mipomersen’s intrinsic qualities as they prepare to go head-to-head against Aegerion’s Juxtapid in the small homozygous familial hypercholesterolemia market. Kynamro also will carry a price tag that is $119,000 less than Juxtapid’s.